Alzamend Neuro Shares Dip With AL001 Trial in Focus, Cash Concerns Linger
Alzamend Neuro Inc. shares slipped late Thursday in U.S. trading. The stock trailed gains in other biotech names as investors looked for an upcoming clinical update from the small drug developer and questioned how it will cover funding requirements. The Nasdaq-listed stock was last at $1.14, off 4 cents. Shares moved in a $1.11 to $1.14 range, with about 14,000 shares traded at last check. The SPDR S&P Biotech ETF, which tracks the wider biotech sector, was in the green, which points to the drop being tied to the stock and not the group as a whole.